12th International Symposium on Hodgkin Lymphoma

ABSTRACT

The proceedings contain 115 papers. The topics discussed include FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients results from the very early pet-response adapted EORTC-COBRA trial;treatment related morbidity in patients with classical Hodgkin lymphoma results of the ongoing, randomized phase III HD21 trial by the German Hodgkin study group;a retrospective study to evaluate the reliability of staging and risk stratification of adolescent and adult patients with Hodgkin's lymphoma registered in the lymphoma clinic at Tata Memorial Center;advanced stage classical Hodgkin lymphoma (CHL) patients with a positive interim-pet (Pet-2) Deauville Score (DS) 5 after 2 ABVD cycles a pooled analysis of individual patient data of three multi-center trials;age, histotype and stage iv are associated with a shorter survival in patients with Hodgkin lymphoma, even the pet-adapted era. a single center retrospective study;clinical outcome of classical Hodgkin lymphoma patients receiving systemic anti-lymphoma treatment during SARS-CoV-2 positivity results from the chemo-covid study on behalf of Fondazione Italiana Linfomi;comparative efficacy of the R-BEACOPP-14 and R-CHOP regimens in the treatment of patients with advanced stages of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with THRLBCL-like histopathological growth patterns in the tumor biopsy;and improved overall survival with first-line brentuximab Vedotin Plus chemotherapy in patients with advanced stage III/IV classical Hodgkin lymphoma an updated analysis of ECHELON-1.